Liraglutide
Victoza (liraglutide) is a brand-name injectable GLP-1 receptor agonist used to treat type 2 diabetes and support weight management. It helps control blood sugar by stimulating insulin release, suppressing glucagon, slowing digestion, and reducing appetite. It is prescribed alongside diet and exercise for adults with type 2 diabetes who need improved glycemic control.
Victoza is an injectable GLP-1 receptor agonist used to manage type 2 diabetes and support weight loss by mimicking incretin hormones that regulate blood sugar and appetite.
Key facts at a glance
- RxNorm
- 897123
- Generic
- Victoza
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Victoza is indicated for type 2 diabetes in adults and children ages 10 and older to improve blood sugar control, along with diet and exercise. It is also prescribed for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Additionally, it reduces the risk of major cardiovascular events (heart attack, stroke) in adults with type 2 diabetes and established heart disease.
Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of incretin hormones. It enhances insulin secretion in response to meals, suppresses glucagon release (reducing liver glucose production), slows gastric emptying to reduce post-meal blood sugar spikes, and promotes feelings of fullness to decrease food intake.
Victoza is administered as a daily subcutaneous injection (not insulin). It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Common side effects include nausea, diarrhea, vomiting, and injection site reactions. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Use cautiously with a history of pancreatitis. Patients should seek emergency care for signs of severe pancreatitis, thyroid tumors, or serious allergic reactions.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy